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Introduction {#sec005}
============

Among all malignant neoplasms worldwide, gastric cancer ranks fifth for cancer incidence and second for cancer deaths \[[@pone.0225958.ref001]\]. Although curative resection (R0) with lymph node dissection plus adjuvant chemotherapy has prolonged the survival of patients with gastric cancer, the recurrence rate of R0 cases remains around 30% in patients at stage II/III \[[@pone.0225958.ref002], [@pone.0225958.ref003]\]. Peritoneal recurrence is the most frequent recurrence pattern in patients with gastric cancer after curative resection, and as such, peritoneal recurrence is the most common cause of subsequent cancer death \[[@pone.0225958.ref004]--[@pone.0225958.ref007]\].

The exposure of cancer cells to the serosal surface (i.e., T4) is a common risk factor for and accounts for most cases of peritoneal recurrence \[[@pone.0225958.ref008], [@pone.0225958.ref009]\]. However, peritoneal recurrence can develop in not only T4 cases but also cases without the exposure of cancer cells to the serosal surface (i.e., T3). According to the Japanese Research Society for Gastric Cancer, peritoneal recurrence was the cause of death in 2.3% of T1 cases, 6.9% of T2 cases, 17.2% of T3 cases, 33.4% of T4 cases of gastric cancer\[[@pone.0225958.ref009]\].

It has been reported that E-cadherin is one of important factors for tumor invasion and distant metastasis in some solid cancers\[[@pone.0225958.ref008], [@pone.0225958.ref010]--[@pone.0225958.ref012]\]. Taken together, we previously reported the correlation between the microscopic distance from the tumor invasion front to the serosa (DIFS) and serosal exposure of gastric cancer cells, and speculated that DIFS might be associated with peritoneal recurrence\[[@pone.0225958.ref003]\]. Then, in this study we focused on the significance of DIFS and E-cadherin in peritoneal recurrence.

The present study was conducted to clarify the risk factors of peritoneal recurrence after R0 surgery for T3-stage gastric cancer.

Materials and methods {#sec006}
=====================

Patients {#sec007}
--------

A total of Ninety-six patients with gastric cancer, who received gastrectomy between 2000 and 2016 at Osaka City University, were enrolled in this study. The inclusion criteria were as follows; 1. histologically proven gastric adenocarcinoma; 2. the depth of tumor invasion was T3; 3. curative operation; 4. intraoperative peritoneal lavage cytology-negative ([Fig 1](#pone.0225958.g001){ref-type="fig"}). Since the peritoneal recurrence of T1 and T2 cancers has been considered to develop via trans-lymphatic pathway\[[@pone.0225958.ref013], [@pone.0225958.ref014]\], we excluded T1 and T2 cases in this study. The follow-up period was 60 months, and the median follow-up was 49.3 months. The follow-up program of postoperative surveillance consisted of computed tomography, and ultrasound performed every 3 months in order to diagnose recurrent diseases.

![The inclusion criteria in flowchart.\
The inclusion criteria were as follows; 1. histologically proven gastric adenocarcinoma; 2. the depth of tumor invasion was T3; 3. curative operation; 4. intraoperative peritoneal lavage cytology-negative (Fig 1).](pone.0225958.g001){#pone.0225958.g001}

The pathological data was recorded according to the eighth edition of TNM Classification\[[@pone.0225958.ref015]\]. Pathologic examination was performed using the section which include center of the tumor. Macroscopic type were determined according to the Japanese Gastric Cancer Association classification with third English edition\[[@pone.0225958.ref016]\]. This study was approved by the Osaka City University Ethics Committee (approval number 924). Written informed consent for research was obtained from patients.

Immunohistochemical techniques {#sec008}
------------------------------

After gastrectomy, the gastric tumor was immediately treated with 10% formalin neutral buffer solution for 24--72 hours. Paraffin-embedded sections were de-paraffinized in xylene and de-hydrated through graded ethanol. The sections were heated for 10 min at 105°C by autoclave in Target Retrieval Solution (DAKO, Carpinteria, CA, USA). Then sections were incubated with 3% hydrogen peroxide to block endogenous peroxidase activity before immunohistochemistry using the following antibodies: anti pan-cytokeratin (26411-1-AP, 1:2000; Proteintech, Rosemont, IL, USA) and anti E-cadherin (NCH-38, 1:100; DAKO). The specimens were incubated with E-cadherin and pan-cytokeratin antibody for overnight at 4°C. The sections were incubated with an appropriate immunoglobulin G for 10 min, followed by three washes with phosphate-buffered saline (PBS). The slides were treated with streptavidin-peroxidase reagent, and were incubated in PBS with diaminobenzidine and 1% (vol/vol) hydrogen peroxide, followed by counterstaining with Mayer's hematoxylin and subsequently examined using light microscopy.

Measurement of the microscopic distance from tumor invasion front to serosa (DIFS) {#sec009}
----------------------------------------------------------------------------------

Pan-cytokeratin staining, that are detectable epithelial components including cancer cells, was used to identify the tumor invasion front. We checked invasion depth of all specimens of the tumor using H-E staining slides. After selecting three specimens with high invasion depth, the three specimens were stained by pan-cytokeratin and measured DIFS of 3 slides. The shortest distance was defined as DIFS of the case. DIFS was measured using the microscope (BZ-X710, Keyence, Osaka, Japan).

Evaluation of E-cadherin expression {#sec010}
-----------------------------------

E-cadherin expression was evaluated by intensity of staining and percentage of stained tumor cells at the invading tumor front: intensity was given scores 0--3 (0 = no, 1 = weak, 2 = moderate, 3 = intense), and frequency of positive cells was determined 0--24%, 25--49%, 50--74%, 75--100%. Expressions were considered positive when intensity scores ≥2 and frequency ≥50%, and negative when intensity scores ≤1 or frequency ≤49%. The pathologist, Dr Sayaka Tanaka, checked DIFS and E-cadherin expression. Dr Togano S, Dr Yashiro M, and Dr Tanaka S checked DIFS and E-cadherin expression.

Statistical analysis {#sec011}
--------------------

The chi-square test was used to determine the significance of the differences between the covariates. The durations from surgery to peritoneal recurrence were estimated by the Kaplan-Meier method and compared using the log-rank test. Multivariate analysis with respect to peritoneal recurrence was performed using logistic regression analysis. Multivariate analysis with respect to five-year overall survival was performed using Cox proportional hazard model. Covariates were selected from those with significant differences in univariate analysis. All statistical analyses were performed using the JMP statistical software (version 13.2; SAS Institute, Cary, NC). Two-sided probability P values of \< 0.05 were considered to be statistically significant.

Results {#sec012}
=======

Correlations between peritoneal recurrence and clinicopathologic features {#sec013}
-------------------------------------------------------------------------

Post-operative recurrence was confirmed at the peritoneum in 16 of the 96 cases. Five of the 16 peritoneal recurrence cases developed liver recurrence, and two developed lymph node recurrence. Tables [1](#pone.0225958.t001){ref-type="table"} and [S1](#pone.0225958.s001){ref-type="supplementary-material"} shows the correlations between peritoneal recurrence and clinicopathologic features. There was a significant correlation between peritoneal recurrence and lymph node metastasis (p = 0.012).

10.1371/journal.pone.0225958.t001

###### Correlation between peritoneal recurrence and clinicopathologic features in 96 cases at T3 stage.

![](pone.0225958.t001){#pone.0225958.t001g}

  Clinicopathologic features                               Peritoneal recurrence (n = 16)   No peritoneal recurrence (n = 80)   p value
  -------------------------------------------------------- -------------------------------- ----------------------------------- ---------
  Age                                                                                                                           
  \< 70 Years                                              10 (16.9%)                       49 (83.1%)                          
  ≥ 70 Years                                               6 (16.2%)                        31 (83.8%)                          0.925
  Sex                                                                                                                           
  Male                                                     6 (19.4%)                        25 (80.6%)                          
  Female                                                   10 (15.4%)                       55 (74.6%)                          0.626
  Macroscopic type[^a^](#t001fn001){ref-type="table-fn"}                                                                        
  type1-2                                                  7 (18.4%)                        31 (81.6%)                          
  type3-4                                                  9 (15.5%)                        49 (84.5%)                          0.709
  Histological type                                                                                                             
  intestinal                                               9 (15.5%)                        49 (84.5%)                          
  diffuse                                                  7 (18.4%)                        31 (81.6%)                          0.709
  LN metastasis[^b^](#t001fn002){ref-type="table-fn"}                                                                           
  negative                                                 3 (6.3%)                         45 (93.7%)                          
  positive                                                 13 (27.1%)                       35 (72.9%)                          0.012
  INF[^c^](#t001fn003){ref-type="table-fn"}                                                                                     
  a/b                                                      9 (12.9%)                        61 (87.1%)                          
  c                                                        7 (30.4%)                        16 (69.6%)                          0.064
  Lymphatic invasion                                                                                                            
  negative                                                 2 (7.7%)                         24 (92.3%)                          
  positive                                                 14 (20.0%)                       56 (80.0%)                          0.221
  Vascular invasion                                                                                                             
  negative                                                 14 (18.9%)                       60 (81.1%)                          
  positive                                                 2 (9.1%)                         20 (90.9%)                          0.278
  Tumor size                                                                                                                    
  \< 50 mm                                                 7 (14.3%)                        42 (85.7%)                          
  ≥ 50 mm                                                  9 (19.1%)                        38 (80.9%)                          0.523
  DIFS[^d^](#t001fn004){ref-type="table-fn"}                                                                                    
  ≤ 234 μm                                                 14 (17.2%)                       44 (82.8%)                          
  \> 234 μm                                                2 (5.3%)                         36 (94.7%)                          0.023
  E-cadherin                                                                                                                    
  negative                                                 7 (24.1%)                        22 (75.9%)                          
  positive                                                 2 (13.4%)                        36 (86.6%)                          0.196

^a^: Macroscopic type; The classification according to the general rules for gastric cancer study of the Japanese Research Society for Gastric Cancer

^b^: LN metastasis; Lymph node metastasis

^c^: INF; Pattern of tumor infiltration into the surrounding tissue. The predominant pattern of infiltrating growth into the surrounding tissue is classified as follows; INF a: The tumor shows expanding growth and a distinct border with the surrounding tissue. INF b: This category is between INF a and INF c. INF c: The tumor shows infiltrating growth and an indistinct border with the surrounding tissue.

^d^: DIFS; the microscopic distance from tumor invasion front to serosa

Correlations between peritoneal recurrence and the DIFS or E-cadherin expression {#sec014}
--------------------------------------------------------------------------------

Pan-cytokeratin was expressed mainly in the cell membrane of the cancer cells ([Fig 2](#pone.0225958.g002){ref-type="fig"}). The DIFS of the tumors with peritoneal recurrence (156±220 μm, mean±std. dev.) was significantly shorter than that of the tumors without peritoneal recurrence (360±478 μm) (p = 0.011, t-test). The cutoff value for the DIFS was determined as 234 μm based on the results of the receiver operating characteristics (ROC) curve ([Fig 3](#pone.0225958.g003){ref-type="fig"}).

![The microscopic distance from the tumor invasion front to the serosa.\
The microscopic distance from the tumor invasion front to the serosa (DIFS) was calculated by H&E staining and/or pan-cytokeratin staining. Pan-cytokeratin staining was used to determine the cancer cells at the invasion front.](pone.0225958.g002){#pone.0225958.g002}

![Receiver operating characteristic (ROC) curve with the DIFS.\
The cutoff value for DIFS was 234 μm.](pone.0225958.g003){#pone.0225958.g003}

E-cadherin was mainly expressed in the cell membrane of cancer cells ([Fig 4](#pone.0225958.g004){ref-type="fig"}). [Table 1](#pone.0225958.t001){ref-type="table"} shows the correlations between peritoneal recurrence and the DIFS or E-cadherin expression. Peritoneal recurrence was significantly correlated with DIFS ≤234 μm (p = 0.023), but not with E-cadherin expression.

![E-cadherin staining.\
E-cadherin was expressed mainly at the cell membrane.](pone.0225958.g004){#pone.0225958.g004}

Risk factors of peritoneal recurrence {#sec015}
-------------------------------------

[Table 2](#pone.0225958.t002){ref-type="table"} summarizes the results of the univariate and multivariate analyses with respect to peritoneal recurrence. A DIFS ≤234 μm and lymph node metastasis were independent risk factors for peritoneal recurrence (p = 0.049, p = 0.023, respectively).

10.1371/journal.pone.0225958.t002

###### Univariate and multivariate analysis with respect to peritoneal recurrence.

![](pone.0225958.t002){#pone.0225958.t002g}

                                                        Univariate analysis   Multivariate analysis                                   
  ----------------------------------------------------- --------------------- ----------------------- ------- ------- --------------- -------
  E-cadherin                                                                                                                          
  positive vs negative                                  2.051                 0.681--6.178            0.202                           
  DIFS[^a^](#t002fn001){ref-type="table-fn"}                                                                                          
  \> 234 μm vs ≤ 234 μm                                 5.727                 1.221--26.868           0.027   4.862   1.005--23.516   0.049
  Macroscopic type                                                                                                                    
  type1-2 vs type3-4                                    0.813                 0.275--2.408            0.709                           
  Histological type                                                                                                                   
  intestinal vs diffuse                                 1.229                 0.415--3.639            0.710                           
  LN metastasis[^b^](#t002fn002){ref-type="table-fn"}                                                                                 
  negative vs positive                                  5.571                 1.472--21.083           0.011   4.846   1.249--18.803   0.023
  Lymphatic invasion                                                                                                                  
  negative vs positive                                  3.000                 0.632--14.232           0.167                           
  Vascular invasion                                                                                                                   
  negative vs positive                                  0.429                 0.090--2.051            0.429                           
  Tumor size                                                                                                                          
  \< 50 mm vs ≥ 50 mm                                   1.421                 0.482--4.188            0.524                           

^a^: DIFS; the microscopic distance from tumor invasion front to serosa

^b^: LN metastasis; Lymph node metastasis

Survival {#sec016}
--------

[Fig 5](#pone.0225958.g005){ref-type="fig"} provides the Kaplan-Meier survival curve for the 96 patients. The prognosis of the patients with a DIFS ≤234 μm was significantly poorer than that of the patients with a DIFS \>234 μm (log rank, p = 0.007). The prognosis of the lymph node metastasis (N1) patients was significantly poorer than that of the patients without lymph node metastasis (N0) (log rank, p = 0.017). In contrast, no significant correlation was found between E-cadherin expression and prognosis. A multivariate analysis with respect to five-year overall survival revealed that DIFS ≤234 μm and lymph node metastasis were significantly (p = 0.005, and p = 0.032, respectively) correlated with survival ([Table 3](#pone.0225958.t003){ref-type="table"}).

![Survival of the patients with gastric cancer.\
The five-year overall survival of all patients (n = 96) based on the DIFS and on the E-cadherin expression. The Kaplan-Meier survival curve indicates that the five-year overall survival of the patients with a DIFS ≤234 μm was significantly worse than that of the patients with a DIFS \>234 (p = 0.007). E-cadherin expression was not associated with the prognosis.](pone.0225958.g005){#pone.0225958.g005}

10.1371/journal.pone.0225958.t003

###### Univariate and multivariate analysis with respect to five-year overall survival.

![](pone.0225958.t003){#pone.0225958.t003g}

                                                        Univariate analysis   Multivariate analysis                                    
  ----------------------------------------------------- --------------------- ----------------------- ------- ------- ---------------- -------
  E-cadherin                                                                                                                           
  positive vs negative                                  1.260                 0.387--3.649            0.683                            
  DIFS[^a^](#t003fn001){ref-type="table-fn"}                                                                                           
  \> 234 μm vs ≤ 234 μm                                 9.834                 1.955--178.670          0.003   8.752   1.670--160.900   0.005
  Macroscopic type                                                                                                                     
  type1-2 vs type3-4                                    1.245                 0.430--4.051            0.692                            
  Histological type                                                                                                                    
  intestinal vs diffuse                                 0.884                 0.272--2.559            0.884                            
  LN metastasis[^b^](#t003fn002){ref-type="table-fn"}                                                                                  
  negative vs positive                                  4.186                 1.306--18.514           0.015   3.582   1.091--16.104    0.032
  Lymphatic invasion                                                                                                                   
  negative vs positive                                  2.516                 0.685--16.180           0.181                            
  Vascular invasion                                                                                                                    
  negative vs positive                                  0.941                 0.213--3.018            0.925                            
  Tumor size                                                                                                                           
  \<50 mm vs ≥50 mm                                     1.046                 0.358--3.054            0.934                            

^a^: DIFS; the microscopic distance from tumor invasion front to serosa

^b^: LN metastasis; Lymph node metastasis

Discussion {#sec017}
==========

The DIFS was associated with peritoneal recurrence. The cut-off value of DIFS was determined as 234 μm in accordance with the ROC curve analysis. In the multivariate analysis, DIFS ≤234 μm was an independent risk factor for peritoneal recurrence. These findings suggest that the DIFS is an important pathologic factor that could be used to predict the prognosis of patients with T3-stage gastric cancer.

According to guideline, tegafur-gimeracil-oteracil (S-1) monotherapy is recommended for the gastric cancer patients with stage II, and oxaliplatin combination therapy is recommended for the gastric cancer patients with stage III in Japan\[[@pone.0225958.ref002], [@pone.0225958.ref017]--[@pone.0225958.ref019]\]. Our study might suggest that oxaliplatin combination therapy may be recommended not only for stage III but also for stage II with DIFS ≤ 234 μm.

There were no significant factors associated with DIFS ≤234μm, but which tended to be associated with lymph node metastasis (p = 0.095; [S1 Table](#pone.0225958.s001){ref-type="supplementary-material"}). Lymph node metastasis was correlated with peritoneal recurrence in our study. It has been reported that peritoneal recurrence is caused by gastric cancer cells leave the primary tumor, adhere to the peritoneum, and proliferate at the site of adherence, resulting in the development of peritoneal recurrence\[[@pone.0225958.ref020], [@pone.0225958.ref021]\]. But some studies have suggested that peritoneal metastasis in gastric cancer without serosal invasion may occur via trans-lymphatic pathway\[[@pone.0225958.ref013], [@pone.0225958.ref022]\]. As for T3-stage gastric cancer with DIFS ≤234μm, our study might suggest same hypothesis.

It has been reported that E-cadherin, a cell-cell adhesion molecule, plays an important role in tumor invasion and distant metastasis such as peritoneal recurrence\[[@pone.0225958.ref012], [@pone.0225958.ref023], [@pone.0225958.ref024]\]. However, in the present study, no significant correlation was found between E-cadherin expression and peritoneal recurrence in gastric cancer at stage T3. One of the reasons why E-cadherin did not affect the peritoneal recurrence of T3 cases might be that E-cadherin might affect the invasion activity of cancer cells at early T-stage such as T1 and T2, but not advanced T-stage such as T3 and T4.

In addition to H&E staining, pan-cytokeratin staining was used to evaluate the cancer cells at the invasion front. Pan-cytokeratin was expressed mainly in the cell membrane of cancer cells. The combination of pan-cytokeratin staining and H&E staining was a useful method to determine the cancer cells at the invasion front, especially for undifferentiated tumors. Pan-cytokeratin staining, which stains epithelial elements, makes the invasion front of cancer cells clear.

There may be limitations in this study. Since it is difficult to examine the whole lesions of tumor, it is uncertain that the obtained section represented most invasive lesion of cancer cells.

In conclusion, the measurement of the DIFS might be useful for the prediction of peritoneal recurrence among gastric cancer patients who have undergone R0 curative surgery.

Supporting information {#sec018}
======================

###### Correlation between peritoneal recurrence and clinicopathologic features in 96 gastric cancer cases at T3 stage.
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**Do you want your identity to be public for this peer review?** For information about this choice, including consent withdrawal, please see our [Privacy Policy](https://www.plos.org/privacy-policy).
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Reviewer \#3: Yes: Masayuki Watanabe

Reviewer \#4: Yes: Shinichiro Hasegawa

\[NOTE: If reviewer comments were submitted as an attachment file, they will be attached to this email and accessible via the submission site. Please log into your account, locate the manuscript record, and check for the action link \"View Attachments\". If this link does not appear, there are no attachment files to be viewed.\]

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, <https://pacev2.apexcovantage.com/>. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Registration is free. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at <figures@plos.org>. Please note that Supporting Information files do not need this step.

10.1371/journal.pone.0225958.r002

Author response to Decision Letter 0

31 Oct 2019

Dear Kun Yang Ph.D.

Academic Editor

We greatly appreciate your invitation for us to revise our article "Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric cancer". We would like to thank you for a number of comments and suggestions for improvement in our manuscript. We have carefully considered the referees' comments and have made point-by-point responses as described below. Also, we highlight all changes in the revised manuscript. This manuscript is not being considered in whole or in part by any other journal. All authors are aware of the content of this manuscript.

We hope you will seriously consider this report for publication in PLOS ONE.

Dear Reviewer\#1

Thank you very much for the careful review of the Reviewer \#1. We corrected several points according to the descriptions by the Reviewer \#1, as described below. We indicated the changes point by point and highlighted them in the revised paper.

1\. This study evaluated only T3-gastric cancer.

I suggest to change the title. \"gastric cancer\" to \"T3-gastric cancer\"

According to the reviewer\#1\'s comment, we change the title, \"Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric caner\". (on page 1, line 3)

2\. Why did the authors focus on the microscopic distance from the tumor invasion front to the serosa (DIFS) and E-cadherin. Please mentioned in Introduction section.

It has been reported that E-cadherin is one of important factors for tumor invasion and distant metastasis in some solid cancers \[8, 10-12\]. Taken together, we previously reported the correlation between DIFS and serosal exposure of gastric cancer cells, and speculated that DIFS might be associated with peritoneal recurrence \[3\]. Then, in this study we focused on the significance of DIFS and E-cadherin in peritoneal recurrence. We added the comments in the introduction. (on page 3 line 40-45)

\[3\] Miki Y, Yashiro M, Ando K, Okuno T, Kitayama K, Masuda G, et al. Examination of cancer cells exposed to gastric serosa by serosal stamp cytology plus RT-PCR is useful for the identification of gastric cancer patients at high risk of peritoneal recurrence. Surgical oncology. 2017;26(4):352-8. Epub 2017/11/09. doi: 10.1016/j.suronc.2017.07.008. PubMed PMID: 29113652.

\[8\] Sun F, Feng M, Guan W. Mechanisms of peritoneal dissemination in gastric cancer. Oncology letters. 2017;14(6):6991-8. Epub 2018/01/19. doi: 10.3892/ol.2017.7149. PubMed PMID: 29344127; PubMed Central PMCID: PMCPMC5754894.

\[10\] Gao M, Zhang X, Li D, He P, Tian W, Zeng B. Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma. Oncotarget. 2016;7(51):85502-14. Epub 2016/12/03. doi: 10.18632/oncotarget.13453. PubMed PMID: 27907907; PubMed Central PMCID: PMCPMC5356753.

\[11\] Liang G, Ding M, Lu H, Cao NA, Niu Y, Gao Y, et al. Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncology letters. 2015;10(3):1527-32. Epub 2015/12/02. doi: 10.3892/ol.2015.3475. PubMed PMID: 26622703; PubMed Central PMCID: PMCPMC4533732.

\[12\] Torabizadeh Z, Nosrati A, Sajadi Saravi SN, Yazdani Charati J, Janbabai G. Evaluation of E-cadherin Expression in Gastric Cancer and Its Correlation with Clinicopathologic Parameters. International journal of hematology-oncology and stem cell research. 2017;11(2):158-64. Epub 2017/09/07. PubMed PMID: 28875011; PubMed Central PMCID: PMCPMC5575728.

3\. Please clarify the inclusion criteria. The authors should describe the study period and flow chart.

The inclusion criteria were as follows; 1. histologically proven gastric adenocarcinoma; 2. the depth of tumor invasion was T3; 3. curative operation; 4. intraoperative peritoneal lavage cytology-negative. The follow-up period was 60 months, and the median follow-up was 49.3 months. We described these criteria in the materials and Fig. 1. (on page 4 line 52-58)

4\. The authors have used the UICC/AJCC 7th edition staging manual. Please use the most current staging manual.

We changed the 7th edition of TNM Classification to the 8th edition of TNM Classification \[15\]. (on page 5 line 71)

\[15\] Brierley JD, Gospodarowicz MK, Writtekind C. TNM Classification of Malignant Tumours, 8th Edition 2016.

5\. As the authors mentioned in Introduction section, we sometimes experienced peritoneal recurrence even in T1-2 cancer patients. Why T1-2 cancer was not included in this analysis? They should include T1-2 cancers in this study.

Since the peritoneal recurrence of T1 and T2 cancers has been considered to develop via trans-lymphatic pathway \[13, 14\], we excluded T1 and T2 cases in this study. (on page 4 line 55-57)

\[13\] Yoshida M, Sugino T, Kusafuka K, Nakajima T, Makuuchi R, Tokunaga M, et al. Peritoneal dissemination in early gastric cancer: importance of the lymphatic route. Virchows Arch. 2016;469(2):155-61. Epub 2016/05/26. doi: 10.1007/s00428-016-1960-7. PubMed PMID: 27220762.

\[14\] Yamamoto M, Taguchi K, Baba H, Endo K, Kohnoe S, Okamura T, et al. Peritoneal dissemination of early gastric cancer: report of a case. Surgery today. 2006;36(9):835-8. Epub 2006/08/29.

6\. In this analysis, location of the tumor (Upper/ Middle/ Lower and Anterior/ Posterior/ Grater curvature side/ Lesser curvature side) was not included. These factors should be included.

We included the tumor location in S1 Table.

Dear Reviewer\#2

Thank you very much for the careful review of the Reviewer \#2. We correct several points according to the descriptions by the Reviewer \#2, as follows.

1\. Did the authors examine peritoneal washing cytology? If so, the authors should describe the result and analyze the relationship between peritoneal recurrence and cytology.

We performed peritoneal washing cytology in all cases. Peritoneal washing cytology-positive cases were excluded in this study, which was described in the materials and Fig. 1. (on page 4 line 52-55)

2\. The authors should show the clinicopathological features in more detail in Table 1, including tumor location, type of gastrectomy, extent of lymph node dissection, and the number of the patients who underwent adjuvant chemotherapy.

We added the detail of clinicopathological features, including tumor location, type of gastrectomy, extent of lymph node dissection, and the number of the patients who underwent adjuvant chemotherapy in S1 Table.

3\. In Material and methods section (page 5, line 77-82), the author should describe who evaluated E-cadherin IHC staining (e.g. by experienced pathologist unaware of clinical data). If possible, the authors should perform the agreement study of E-cadherin expression and show the concordance between the two pathologist.

The pathologist, Dr Sayaka Tanaka, checked DIFS and E-cadherin expression. Dr Togano S, Dr Yashiro M, and Dr Tanaka S checked DIFS and E-cadherin expression. We added these comments in the materials and methods. (on page 6 line 119-121)

4\. The authors should discuss several limitations of this study in Discussion section.

We added limitations in the manuscript, as follows. Since it is difficult to examine the whole lesions of tumor, it is uncertain that the obtained section represented most invasive lesion of cancer cells. (on page 14 line 347-349)

5\. Please recheck the grammar and terminology.

The manuscript was proofread by a professional editor and native English speaker.

6\. The statistical method for the multivariate analysis is unclear.

Multivariate analysis with respect to peritoneal recurrence was performed using logistic regression analysis. Multivariate analysis with respect to five-year overall survival was performed using Cox proportional hazard model. Covariates were selected from those with significant differences in univariate analysis. (on page 7 line 130-133)

Dear Reviewer\#3

Thank you very much for the careful review of the Reviewer \#3. We correct several points according to the descriptions by the Reviewer \#3, as follows.

1\. The authors focused on the risk factors of peritoneal metastasis after curative resection for T3 gastric cancer. The title does not include the information that this study especially focused on T3 gastric cancer.

According to the reviewer\'s comments, we changed the title, \"Microscopic distance from tumor invasion front to serosa might be a useful predictive factor for peritoneal recurrence after curative resection of T3-gastric cancer\" (on page 1, line 3)

2\. The follow-up period of the study cohort is very important information for readers. Besides, it is also important how these patients were followed up. The authors should provide the information on the follow-up period, timing and modality for follow-up.

We added follow-up period, timing and modality in Materials and Method section, as follows. The follow-up period was 60 months, and the median follow-up was 49.3 months. The follow-up program of postoperative surveillance consisted of computed tomography, and ultrasound performed every 3 months in order to diagnose recurrent diseases. (on page 4 line 57-60)

3\. Adjuvant chemotherapy may influence the survival of patients. Please include the information on presence or absence of adjuvant chemotherapy into the background.

We included the data of adjuvant chemotherapy in S1 Table.

4\. When discussing the DIFS, the preparation of tissue section for pathology is very important information. Please provide the details of preparation for tissue section.

The preparation of tissue section was as follows. After gastrectomy, the gastric tumor was immediately treated with 10% formalin neutral buffer solution for 24-72 hours. We added the comments in Materials and Method section. (on page 5 line 79-80)

5\. Please provide the C-statistic of the ROC curve shown in Figure 2.

We added the C-statistic (0.66) in Figure 2.

6\. The authors should describe the detail of multivariate analysis. How did they select the covariates?

Multivariate analysis with respect to peritoneal recurrence was performed using logistic regression analysis. Multivariate analysis with respect to five-year overall survival was performed using Cox proportional hazard model. Covariates were selected from those with significant differences in univariate analysis. (on page 7 line 130-133)

7\. The discussion seems to be poor. Please discuss why the expression of E-Cadherin did not influence the peritoneal metastasis in this study cohort, and the clinical evidence of adjuvant therapy to decrease peritoneal recurrence. Also, they should declare the limitation of this study.

One of the reasons why E-cadherin did not affect the peritoneal recurrence of T3 cases might be that E-cadherin might affect the invasion activity of cancer cells at early T-stage such as T1 and T2, but not advanced T-stage such as T3 and T4. (on page 13 line 334- page 13 line 340)

According to guideline, tegafur-gimeracil-oteracil (TS-1) monotherapy is recommended for the gastric cancer patients with stage II, and oxaliplatin combination therapy is recommended for the gastric cancer patients with stage III in Japan \[2.17-19\]. Our study might suggest that oxaliplatin combination therapy may be recommended not only for stage III but also for stage II with DIFS ≤ 234 μm. (on page 13 line 317-321).

We added limitations in the manuscript, as follows. Since it is difficult to examine the whole lesions of tumor, it is uncertain that the obtained section represented most invasive lesion of cancer cells. (on page 14 line 348-350).

\[2\] Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. The New England journal of medicine. 2007;357(18):1810-20. Epub 2007/11/06. doi: 10.1056/NEJMoa072252. PubMed PMID: 17978289.

\[17\] Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2011;29(33):4387-93. Epub 2011/10/20. doi: 10.1200/jco.2011.36.5908. PubMed PMID: 22010012.

\[18\] Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial. Lancet (London, England). 2012;379(9813):315-21. Epub 2012/01/10. doi: 10.1016/s0140-6736(11)61873-4. PubMed PMID: 22226517.

\[19\] Noh SH, Park SR, Yang HK, Chung HC, Chung IJ, Kim SW, et al. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet Oncology. 2014;15(12):1389-96. Epub 2014/12/03. doi: 10.1016/s1470-2045(14)70473-5. PubMed PMID: 25439693.

Dear Reviewer\#4

Thank you very much for the careful review of the Reviewer \#4. We correct several points according to the descriptions by the Reviewer \#4, as follows.

Major points

1\. DIFS is very important in this article. So they should describe the precise method to measure the DIFS. For example, how many did they check to confirm the invasion front. They should clarify the identification of DIFS in details.

We checked invasion depth of all specimens of the tumor using H-E staining slides. After selecting three specimens with high invasion depth, the three specimens were stained by Pan-cytokeratin and measured DIFS of 3 slides. The shortest distance was defined as DIFS of the case. We added the comments in Materials and Method section. (on page 6 line 108-111)

2\. They classified the patients to peritoneal recurrence and non-recurrence groups. How long did they observe those patients? They should describe the observation period.

The follow-up period was 60 months, and the median follow-up was 49.3 months. We added follow-up period in Materials and Method section. (on page 4 line 57-58)

3\. The explanation of the importance of E-cadherin in gastric cancer patients is necessary.

It has been reported that E-cadherin is one of important factors for tumor invasion and distant metastasis in some solid cancers \[8, 10-12\]. We added the comments in the introduction. (on page 3 line 40-45)

\[8\] Sun F, Feng M, Guan W. Mechanisms of peritoneal dissemination in gastric cancer. Oncology letters. 2017;14(6):6991-8. Epub 2018/01/19. doi: 10.3892/ol.2017.7149. PubMed PMID: 29344127; PubMed Central PMCID: PMCPMC5754894.

\[10\] Gao M, Zhang X, Li D, He P, Tian W, Zeng B. Expression analysis and clinical significance of eIF4E, VEGF-C, E-cadherin and MMP-2 in colorectal adenocarcinoma. Oncotarget. 2016;7(51):85502-14. Epub 2016/12/03. doi: 10.18632/oncotarget.13453. PubMed PMID: 27907907; PubMed Central PMCID: PMCPMC5356753.

\[11\] Liang G, Ding M, Lu H, Cao NA, Niu Y, Gao Y, et al. Metformin upregulates E-cadherin and inhibits B16F10 cell motility, invasion and migration. Oncology letters. 2015;10(3):1527-32. Epub 2015/12/02. doi: 10.3892/ol.2015.3475. PubMed PMID: 26622703; PubMed Central PMCID: PMCPMC4533732.

\[12\] Torabizadeh Z, Nosrati A, Sajadi Saravi SN, Yazdani Charati J, Janbabai G. Evaluation of E-cadherin Expression in Gastric Cancer and Its Correlation with Clinicopathologic Parameters. International journal of hematology-oncology and stem cell research. 2017;11(2):158-64. Epub 2017/09/07. PubMed PMID: 28875011; PubMed Central PMCID: PMCPMC5575728.

4\. DIFS and lymph node metastasis are independent predictive factors for peritoneal recurrence. So they should add subgroup analysis in T3, lymph node metastasis negative patients.

We performed subgroup analysis for lymph node metastasis negative patients (n=48), positive patients (n=48). Only 3 cases developed in lymph node metastasis negative patients (n=48). There was no significant correlation between DIFS ≤234 μm and peritoneal recurrence (data not shown).

Minor points

1\. In Table1, they should include DIFS and E-cadherin expression.

2\. In line 189, "by H&E staining" is unnecessary.

According to the comment, we include DIFS and E-cadherin expression to Table 1 and omit a sentence, "by H&E staining" In line 189.

Dear Reviewer\#5

Thank you very much for the careful review of the Reviewer \#5. We correct several points according to the descriptions by the Reviewer \#5, as follows.

1\. The authors measured the microscopic distance from the tumor invasion front to the serosa (DIFS) using tissue slides by H&E staining and pan-cytokeratin. However, there are no description about the numbers of slides they evaluated the DIFS. It might be necessary to measure at least 3 slides per case to evaluate DIFS precisely.

We checked invasion depth of all specimens of the tumor using H-E staining slides. After selecting three specimens with high invasion depth, the three specimens were stained by Pan-cytokeratin and measured DIFS of 3 slides. The shortest distance was defined as DIFS of the case. We added the comments in Materials and Method section. (on page 6 line 108-111)

2\. The authors did not mention about the adjuvant chemotherapy. The authors should describe the presence or absence of adjuvant chemotherapy, and also indicate the contents of adjuvant chemotherapy.

We showed the data of adjuvant chemotherapy in S1 Table.

3\. The authors pointed out that the lymph node metastasis were independent risk factors for peritoneal recurrence. And they assumed that the serosal invasion may occur via translymphatic pathway. It should be desireble to present the mechanism of serosal invasion may occur via translymphatic pathway. And they should evaluate the exposure of cancer cell at the surface of lymph node which the cancer cells metastases.

We commented as follows; peritoneal recurrence in gastric cancer without serosal invasion may occur via trans-lymphatic pathway. (on page 13 line 327-330)

Evaluation of the exposure of cancer cells from the lymph nodes may be useful to prove peritoneal recurrence via trans-lymphatic pathway. However, lymph node metastasis might be secondary developed after peritoneal recurrence. Therefore, it is difficult to evaluate whether peritoneal metastasis might occur via trans-lymphatic pathway or serosal exposure of cancer cells.
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Dear Dr. Yashiro,

We are pleased to inform you that your manuscript has been judged scientifically suitable for publication and will be formally accepted for publication once it complies with all outstanding technical requirements.

Within one week, you will receive an e-mail containing information on the amendments required prior to publication. When all required modifications have been addressed, you will receive a formal acceptance letter and your manuscript will proceed to our production department and be scheduled for publication.

Shortly after the formal acceptance letter is sent, an invoice for payment will follow. To ensure an efficient production and billing process, please log into Editorial Manager at <https://www.editorialmanager.com/pone/>, click the \"Update My Information\" link at the top of the page, and update your user information. If you have any billing related questions, please contact our Author Billing department directly at <authorbilling@plos.org>.

If your institution or institutions have a press office, please notify them about your upcoming paper to enable them to help maximize its impact. If they will be preparing press materials for this manuscript, you must inform our press team as soon as possible and no later than 48 hours after receiving the formal acceptance. Your manuscript will remain under strict press embargo until 2 pm Eastern Time on the date of publication. For more information, please contact <onepress@plos.org>.
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Kun Yang
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5\. Is the manuscript presented in an intelligible fashion and written in standard English?

PLOS ONE does not copyedit accepted manuscripts, so the language in submitted articles must be clear, correct, and unambiguous. Any typographical or grammatical errors should be corrected at revision, so please note any specific errors here.

Reviewer \#1: Yes

Reviewer \#2: Yes

Reviewer \#3: Yes

Reviewer \#4: (No Response)

\*\*\*\*\*\*\*\*\*\*

6\. Review Comments to the Author

Please use the space provided to explain your answers to the questions above. You may also include additional comments for the author, including concerns about dual publication, research ethics, or publication ethics. (Please upload your review as an attachment if it exceeds 20,000 characters)
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